The number of endothelial progenitor cells predicts the treatment response in non-squamous non-small-cell lung cancer patients treated with combined chemotherapy and bevacizumab
| Project/Area Number |
26461152
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Akita University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 腫瘍血管新生 / テーラーメード治療 / バイオマーカー / 血管内皮前駆細胞 / 抗癌剤のテーラーメード治療 |
|---|
| Outline of Final Research Achievements |
Bevacizumab targets tumor angiogenesis, which is the standard approach to be combined with chemotherapy. Also, the number of circulating EPCs is known to be tumor angiogenesis marker. This study aimed to investigate the association between the number of EPCs when treated with chemotherapy in combination with bevacizumab and the disease outcomes in NSCLC patients.
We identified NSCLC patients who had not received any treatment. We divided into two groups relative to the level of EPCs. In each group we compared the tumor reduction ratio, progression-free survival, the objective response ratio, and the disease control ratio with or without administering Bevacizumab in combination. Only in the high EPC group, chemotherapy in combination with bevacizumab produced a significantly higher tumor reduction ratio and ORR and significantly longer PFS compared to the absence of bevacizumab. The number of EPCs may act as a biomarker for predicting the additional effect of Bev. in NSCLC patients.
|
Report
(4 results)
Research Products
(13 results)
-
-
-
-
[Presentation] HIGH ENDOTHELIAL PROGENITOR CELLS INDUCE A HIGH RESPONSE IN PATIENTS TREATED WITH CHEMOTHERAPY IN COMBINATION WITH BEVACIZUMAB IN NON-SMALL NON-SQUAMOUS LUNG CANCER2016
Author(s)
Kazuhisa Sudo, Kazuhiro Sato, Yuji Okuda,Yukiyasu Hasegawa, Mariko Asano, Masahide Takeda, Kenji Iino,Masaaki Sano, Masatomo Miura, Hiroyuki Watanabe, Takanobu Shioya, Hiroshi Ito
Organizer
The 21st Congress of the Asian Pacific Society of Respirology
Place of Presentation
Queen Sirikit National Convention Center in Bangkok, Thailand
Year and Date
2016-11-12
Related Report
Int'l Joint Research
-
[Presentation] HIGH PLASMA CONCENTRATION OF GEFITINIB IN PATIENTS WITH EGFR EXON 21 L858R POINT MUTATIONS IS COMPARED TO LOW PLASMA CONCENTRATION, PROGRESSION-FREE SURVIVAL WAS PROLONGED.2016
Author(s)
Yuji Okuda, Kazuhiro Sato, Kazuhisa Sudo, Yukiyasu Hasegawa, Mariko Asano, Masahide Takeda, Kenji Iino,Masaaki Sano, Masatomo Miura, Hiroyuki Watanabe, Takanobu Shioya, Hiroshi Ito
Organizer
The 21st Congress of the Asian Pacific Society of Respirology
Place of Presentation
Queen Sirikit National Convention Center in Bangkok, Thailand
Year and Date
2016-11-12
Related Report
Int'l Joint Research
-
-
-
-
-
-
-
[Presentation] Validity of the Ultrasound Lung Comets Signs for Assessment of Severity of Interstitial Pneumonia2015
Author(s)
M Asano, S Sakamoto, K Sato, Y Okuda, K Sudo, M Takeda, M Sano, S Kibira, H Watanabe, T Shioya, H Ito
Organizer
The ATS international conference
Place of Presentation
Denver, Colorado
Year and Date
2015-05-15
Related Report
Int'l Joint Research
-
